Regeneron reports 36% revenue growth and raises several 2026 cost targets

Regeneron’s third-quarter 2026 revenue rose 36% to $5.116 billion, while GAAP diluted EPS increased 35% to $18.45 and non-GAAP diluted EPS climbed 70% to $20.07; Dupixent sales recorded by Sanofi reached $6.5 billion, EYLEA HD U.S. sales rose 62% to $699 million, and Libtayo sales increased 51% to $550 million. The company expanded its Sanofi collaboration for four long-acting antibodies, receiving a $1.0 billion upfront payment to be recognized as fourth-quarter 2026 revenue and becoming eligible for up to $7.0 billion in additional milestones; Regeneron also updated 2026 guidance, including higher R&D and capital spending and approximately 80% GAAP gross margin on product sales.